Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
Annaliesa S. Anderson, Patrick Caubel, James M. Rusnak
New England Journal of Medicine (2022) Vol. 387, Iss. 11, pp. 1047-1049
Open Access | Times Cited: 98

Showing 1-25 of 98 citing articles:

Therapeutic strategies for COVID-19: progress and lessons learned
Guangdi Li, Rolf Hilgenfeld, Richard J. Whitley, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 6, pp. 449-475
Open Access | Times Cited: 420
Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system
Yuyong Zhou, Karen Anbro Gammeltoft, Line A. Ryberg, et al.
Science Advances (2022) Vol. 8, Iss. 51
Open Access | Times Cited: 173
Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir
Yinkai Duan, Hao Zhou, Xiang Liu, et al.
Nature (2023) Vol. 622, Iss. 7982, pp. 376-382
Closed Access | Times Cited: 103
Efficacy and safety of Paxlovid for COVID-19:a meta-analysis
Qian Zheng, Pengfei Ma, Mingwei Wang, et al.
Journal of Infection (2022) Vol. 86, Iss. 1, pp. 66-117
Open Access | Times Cited: 75
Therapeutics for COVID-19
Sima S. Toussi, Jennifer Hammond, Brian S. Gerstenberger, et al.
Nature Microbiology (2023) Vol. 8, Iss. 5, pp. 771-786
Open Access | Times Cited: 71
Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection
Rinki Deo, Manish C. Choudhary, Carlee Moser, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 3, pp. 348-354
Open Access | Times Cited: 58
SARS-CoV-2 Virologic Rebound With Nirmatrelvir–Ritonavir Therapy
Gregory E. Edelstein, Julie Boucau, Rockib Uddin, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 12, pp. 1577-1585
Open Access | Times Cited: 46
Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study
Carlos King Ho Wong, Kristy T. K. Lau, Ivan Chi Ho Au, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 6, pp. 683-695
Open Access | Times Cited: 45
Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study
Grace Qian, Xiaosong Wang, Naomi J. Patel, et al.
The Lancet Rheumatology (2023) Vol. 5, Iss. 3, pp. e139-e150
Open Access | Times Cited: 43
Early Experience with Modified Dose Nirmatrelvir/Ritonavir in Dialysis Patients with Coronavirus Disease 2019
Swapnil Hiremath, Peter G. Blake, Angie Yeung, et al.
Clinical Journal of the American Society of Nephrology (2023) Vol. 18, Iss. 4, pp. 485-490
Open Access | Times Cited: 39
The Coronavirus Disease 2019 Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated With Nirmatrelvir Plus Ritonavir Versus Untreated Controls
Jay Pandit, Jennifer M. Radin, Danielle Chiang, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 1, pp. 25-31
Open Access | Times Cited: 38
Drug treatment of COVID-19 infection
Grace Lui, Giovanni Guaraldi
Current Opinion in Pulmonary Medicine (2023) Vol. 29, Iss. 3, pp. 174-183
Open Access | Times Cited: 30
SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals
Dallas J. Smith, Anastasia S. Lambrou, Pragna Patel
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 72, Iss. 51, pp. 1357-1364
Open Access | Times Cited: 25
Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models
Robert M. Cox, Carolin M. Lieber, Josef D. Wolf, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 23
Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies
Y.-C. Chung, Ching-Yin Lam, Pak-Hei Tan, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8155-8155
Open Access | Times Cited: 10
Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents
Agnieszka Zagórska, Anna Czopek, Monika Fryc, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 797-797
Open Access | Times Cited: 9
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance
Tin Phan, Ruy M. Ribeiro, Gregory E. Edelstein, et al.
Journal of Virology (2025)
Open Access | Times Cited: 1
Symptoms, Viral Loads, and Rebound Among COVID-19 Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score–Matched Untreated Individuals
Sarah E. Smith-Jeffcoat, Jessica E Biddle, H. Keipp Talbot, et al.
Clinical Infectious Diseases (2023) Vol. 78, Iss. 5, pp. 1175-1184
Open Access | Times Cited: 22
Oral Nirmatrelvir and Ritonavir for Coronavirus Disease 2019 in Vaccinated, Nonhospitalized Adults Aged 18–50 Years
Jeremy Samuel Faust, Ashish Kumar, Jui Shah, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 9, pp. 1257-1264
Closed Access | Times Cited: 18
COVID drug Paxlovid was hailed as a game-changer. What happened?
Max Kozlov
Nature (2023) Vol. 613, Iss. 7943, pp. 224-225
Closed Access | Times Cited: 17
A unifying model to explain frequent SARS-CoV-2 rebound after nirmatrelvir treatment and limited prophylactic efficacy
Shadisadat Esmaeili, Katherine Owens, Jessica Wagoner, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 8
COVID-19 Rebound After VV116 vs Nirmatrelvir-Ritonavir Treatment
Zhitao Yang, Yu Xu, Ruizhi Zheng, et al.
JAMA Network Open (2024) Vol. 7, Iss. 3, pp. e241765-e241765
Open Access | Times Cited: 7
Progress in SARS-CoV-2, diagnostic and clinical treatment of COVID-19
Yang Li, Si-Ming Lu, Jia-Long Wang, et al.
Heliyon (2024) Vol. 10, Iss. 12, pp. e33179-e33179
Open Access | Times Cited: 6
Antiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2, single centre, randomised, double-blind, placebo-controlled trial
Bei Wang, Haijun Li, Mi-mi Cai, et al.
EClinicalMedicine (2023) Vol. 63, pp. 102189-102189
Open Access | Times Cited: 15
Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019
Gordon Chun‐Kau Chan, Grace Lui, Ngai Sze Wong, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 10, pp. 1406-1412
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top